

TARO PHARMACEUTICALS NORTH AMERICA INC.

BALANCE SHEETS

	March 31, 2024	March 31, 2023
	U.S. Dollars	
	Unaudited	
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	\$ 27,792	\$ 27,792
Short-term bank deposits	-	-
Marketable securities	-	-
Other receivables and prepaid expenses:		
Prepaid expenses	-	-
Intercompany balances	-	-
Other	-	-
TOTAL Other receivables and prepaid expenses	-	-
TOTAL CURRENT ASSETS	27,792	27,792
LONG-TERM RECEIVABLES AND OTHER ASSETS	372,627,244	372,627,244
GOODWILL	-	-
INTANGIBLE ASSETS AND DEFERRED COSTS, NET	-	-
TOTAL ASSETS	<u>\$ 372,655,036</u>	<u>\$ 372,655,036</u>
LIABILITIES AND SHAREHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Accounts payable:		
Trade payables	\$ -	\$ -
Other current liabilities:		
Intercompany balances	-	-
Accrued expenses	-	-
Other	-	-
TOTAL Other current liabilities	-	-
TOTAL CURRENT LIABILITIES	-	-
SHAREHOLDERS' EQUITY	<u>372,655,036</u>	<u>372,655,036</u>
	<u>\$ 372,655,036</u>	<u>\$ 372,655,036</u>

Date of approval of the
financial statements

William Coote
VP, Chief Financial Officer

TARO PHARMACEUTICALS NORTH AMERICA INC.

STATEMENTS OF INCOME

	For the year Ended March 31, 2024	For the year Ended March 31, 2023	For the year Ended March 31, 2022
	U.S. Dollars		
	Unaudited		
Sales	\$ -	\$ -	\$ -
Cost of sales	-	-	-
Gross profit	-	-	-
Research and development	-	-	-
Selling and marketing expenses	-	-	-
General and administrative expenses	-	6,689	825
Operating income	-	(6,689)	(825)
Financing income (expenses), net	-	-	-
Other income (expense)	-	-	-
Income before taxes on income	-	(6,689)	(825)
Taxes on income	-	-	-
Net income for the period before subsidiaries and dividend	-	(6,689)	(825)
Dividend income, net	-	-	-
Subsidiaries	-	-	-
Net income for the period	\$ -	\$ (6,689)	\$ (825)